56BBED6E-8ADB-430B-A85C-D3773F929447
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 26.379763469119577
- age_years
- 69
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.496
- ANGIOGENESIS+0.476
- DNA_REPAIR+0.460
- INTERFERON_GAMMA_RESPONSE+0.446
- E2F_TARGETS+0.422
- ALLOGRAFT_REJECTION+0.410
- MYC_TARGETS_V1+0.372
- IL6_JAK_STAT3_SIGNALING+0.360
- OXIDATIVE_PHOSPHORYLATION+0.360
- MYC_TARGETS_V2+0.347
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.419
- KRAS_SIGNALING_DN-0.348
- ESTROGEN_RESPONSE_EARLY-0.283
- ANDROGEN_RESPONSE-0.269
- SPERMATOGENESIS-0.253
- PANCREAS_BETA_CELLS-0.226
- MYOGENESIS-0.220
- UV_RESPONSE_DN-0.218
- MITOTIC_SPINDLE-0.203
- APICAL_SURFACE-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4EA4A8AE-581A-4170-8062-99645CB41337 | — | — | 0.935 |
| 2 | B99430AD-6309-4B90-A0AA-A5B2FA746246 | — | — | 0.931 |
| 3 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.925 |
| 4 | FCD3124F-0F41-448E-B2B9-D9934D4EC1A7 | — | — | 0.919 |
| 5 | FFECD0E9-70C2-44BD-B0B4-E8C4B60B793A | — | — | 0.916 |
| 6 | SRR934883 | — | — | 0.914 |
| 7 | 4B4647B5-1964-49A9-AC25-89AB4A669341 | — | — | 0.913 |
| 8 | CC9815B3-88D0-4376-B96F-B979E1FBD0C7 | — | — | 0.912 |
| 9 | 91E04630-B2A7-448E-8C80-580818C9D7E6 | — | — | 0.911 |
| 10 | E92DD0CC-DD0F-469D-8357-228A4A67DBD6 | — | — | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.496 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.476 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.460 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.446 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.422 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.372 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.347 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.337 | Inavolisib | — uncovered |
| COAGULATION | 0.336 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.322 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.296 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.289 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.278 | Idelalisib | — uncovered |
| APOPTOSIS | 0.275 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.262 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.255 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.247 | Idelalisib | — uncovered |